Merck & Co., Inc.’s portfolio diversification strategy is expected to begin bearing fruit this year, with the company preparing for several new drug and vaccine launches in 2024. Merck expects a new 21-valent pneumococcal vaccine V116, the activin-signaling inhibitor sotatercept for pulmonary arterial hypertension (PAH), and the antibody-drug conjugate patritumab deruxtecan for metastatic EGFR-mutated non-small cell lung cancer to begin contributing to revenue in the second half of the year, if those products are approved as expected.
Merck & Co. Heads Into A Year Of Portfolio Expansion
The company expects new products like the pneumococcal vaccine V116, the PAH treatment sotatercept and the ADC patritumab deruxtecan will begin contributing to revenue growth in the near term.
More from Earnings
More from Business
• By
Private Company Edition: The latest group of drug developers to announce venture capital financings is remarkable for its geographic diversity, from Character Biosciences’ $93m series B round in the US to Augustine’s $85m series B in Belgium to a $29.2m series C for Aculys in Japan.
• By
The head of the Spanish medical dermatology specialist told Scrip that maintaining the status quo will only result in the continent’s life sciences sector slipping further behind the US and China.
• By
Stakeholders are pleading for newly confirmed FDA Commissioner Martin Makary to stand up for the agency's high scientific standards and staff as he begins his term.